The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
68Ga-Based Radiopharmaceuticals: Production and Application Relationship
Open accessAbstract
The contribution of 68Ga to the promotion and expansion of clinical research and routine positron emission tomography (PET) for earlier better diagnostics and individualized medicine is considerable. The potential applications of 68Ga-comprising imaging agents include targeted, pre-targeted and non-targeted imaging. This review discusses the key aspects of the production of 68Ga and 68Ga-based radiopharmaceuticals in the light of the impact of regulatory requirements and endpoint pre-clinical and clinical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
Virgolini, I., Ambrosini, V., Bomanji, J. B., Baum, R. P., Fanti, S., Gabriel, M., Papathanasiou, N. D., Pepe, G., Oyen, W., De Cristoforo, C., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1512-3 · Cited by 442
Heppeler, A., Froidevaux, S., Mäcke, H. R., Jermann, E., Béhé, M., Powell, P., & Hennig, M. (1999) · Chemistry - A European Journal · doi:10.1002/(sici)1521-3765(19990702)5:7<1974::aid-chem1974>3.0.co;2-x · Cited by 337
Prospective of 68Ga-Radiopharmaceutical Development
Velikyan, I. (2014) · Theranostics · doi:10.7150/thno.7447 · Cited by 336
Self-citationBergstr�m, M., Grahn�n, A., & L�ngstr�m, B. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0643-x · Cited by 311
Radiolabelling DOTA-peptides with 68Ga
Breeman, W. A. P., de Jong, M., de Blois, E., Bernard, B. F., Konijnenberg, M., & Krenning, E. P. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1702-y · Cited by 291
Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs
LAPPIN, G., KUHNZ, W., JOCHEMSEN, R., KNEER, J., CHAUDHARY, A., OOSTERHUIS, B., DRIJFHOUT, W., ROWLAND, M., & GARNER, R. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.05.008 · Cited by 241
Velikyan, I., Sundin, A., Sörensen, J., Lubberink, M., Sandström, M., Garske-Román, U., Lundqvist, H., Granberg, D., & Eriksson, B. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.126177 · Cited by 176
Self-citationJanson, E. T., Knigge, U., Dam, G., Federspiel, B., Grønbaek, H., Stålberg, P., Langer, S. W., Kjaer, A., Arola, J., Schalin-Jäntti, C., et al. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1921262 · Cited by 167
Sandström, M., Velikyan, I., Garske-Román, U., Sörensen, J., Eriksson, B., Granberg, D., Lundqvist, H., Sundin, A., & Lubberink, M. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.120600 · Cited by 161
Self-citationThe impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials
Marchetti, S., & Schellens, J. H. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603925 · Cited by 152
Crystal structure and solution dynamics of the lutetium(III) chelate of DOTA
Aime, S., Barge, A., Botta, M., Fasano, M., Danilo Ayala, J., & Bombieri, G. (1996) · Inorganica Chimica Acta · doi:10.1016/0020-1693(96)05130-4 · Cited by 148
Velikyan, I., Sundin, A., Eriksson, B. K., Lundqvist, H., Sørensen, J. C. H., Bergström, M., & Långström, B. (2010) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2009.11.008 · Cited by 140
Self-citationMüeller, D., Klette, I., Baum, R. P., Gottschaldt, M., Schultz, M. K., & Breeman, W. A. P. (2012) · Bioconjugate Chemistry · doi:10.1021/bc300103t · Cited by 124
Selvaraju, R. K., Velikyan, I., Johansson, L., Wu, Z., Todorov, I., Shively, J. E., KANDEEL, F. R., Korsgren, O., & Eriksson, O. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.114066 · Cited by 98
Self-citationGuideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU
Verbruggen, A., Coenen, H. H., Deverre, J.-R., Guilloteau, D., Långström, B., Salvadori, P. A., & Halldin, C. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0853-7 · Cited by 91
Optimal buffer choice of the radiosynthesis of 68Ga–Dotatoc for clinical application
Bauwens, M., Chekol, R., Vanbilloen, H. P., Bormans, G. M., & Verbruggen, A. (2010) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e32833acb99 · Cited by 85
Commentary: The phase 0 microdosing concept
Garner, R. C., & Lappin, G. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02575.x · Cited by 81
The importance of high specific radioactivity in the performance of 68Ga-labeled peptide
Velikyan, I., Beyer, G. J., Bergström‐Pettermann, E., Johansen, P., Bergström, M., & Långström, B. (2008) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2008.03.002 · Cited by 81
Self-citationŠimeček, J., Hermann, P., Wester, H., & Notni, J. (2012) · ChemMedChem · doi:10.1002/cmdc.201200471 · Cited by 78
Chen, X. S., & Wong, S. T. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407722-5.00001-3 · Cited by 74
Molecular Imaging and Radiotherapy: Theranostics for Personalized Patient Management
Velikyan, I. (2012) · Theranostics · doi:10.7150/thno.4428 · Cited by 73
Self-citationFeasibility and availability of 68Ga-labelled peptides
Decristoforo, C., Pickett, R. D., & Verbruggen, A. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1988-5 · Cited by 66
Chakravarty, R., Chakraborty, S., Dash, A. K., & Pillai, M. R. A. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.11.001 · Cited by 61
EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD)
Todde, S., Windhorst, A. D., Béhé, M. P., Bormans, G. M., Decristoforo, C., Faivre-Chauvet, A., Ferrari, V., Gee, A. D., Gulyás, B. Z., Halldin, C., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2866-8 · Cited by 40
68Ga-Labeling of Biotin Analogues and their Characterization
Blom, E., Långström, B., & Velikyan, I. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800538s · Cited by 34
Self-citationFusarinine C, a novel siderophore‐based bifunctional chelator for radiolabeling with Gallium‐68
Zhai, C., Summer, D., Rangger, C. A., Haas, H., Haubner, R., & Decristoforo, C. (2015) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3286 · Cited by 33
Selvaraju, R. K., Bulenga, T. N., Espes, D., Lubberink, M., Sørensen, J. C. H., Eriksson, B. K., Estrada, S., Velikyan, I., & Eriksson, O. (2015) · Europe PMC (PubMed Central) · Cited by 32
Self-citationRadionuclides for Imaging and Therapy in Oncology
Velikyan, I. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407722-5.00017-7 · Cited by 30
Self-citationVelikyan, I., Bulenga, T. N., Selvaraju, R., Lubberink, M., Espes, D., Rosenström, U., & Eriksson, O. (2015) · Europe PMC (PubMed Central) · Cited by 29
Self-citationRobust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE
Velikyan, I., Xu, H. M., Nair, M., & Hall, H. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2011.12.010 · Cited by 26
Self-citationImpurity in 68Ga-Peptide Preparation Using Processed Generator Eluate
Petřík, M., Ocak, M., Rupprich, M., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.070953 · Cited by 13
The Diversity of 68Ga-Based Imaging Agents
Velikyan, I. (2012) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-27994-2_7 · Cited by 12
Self-citation
Cited by
Radioactive Main Group and Rare Earth Metals for Imaging and Therapy
Kostelnik, T. I., & Orvig, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00294 · Cited by 483
Metadata
- Authors
- Velikyan, I.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2015-07-16
- Volume
- 20
- Issue
- 7
- Pages
- 12913-12943
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W1610851198
- Cited by
- 255
- References
- 33
- FWCI
- 11.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.